CLOs on the Move

ASP Global

www.aspglobal.com

 
We help you reach your savings targets and your patient experience goals by designing and delivering supplies and patient care products.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.aspglobal.com
  • 3450, Atlanta Industrial Parkway Northwest
    Atlanta, GA USA 30331
  • Phone: 404.696.6999

Executives

Name Title Contact Details

Similar Companies

Beech Brook

Helping children & families thrive by promoting healthy child development, strengthening the ability to overcome adversity, & enhancing family health & stability.

Accugenix

Accugenix offers a fixed pricing structure based upon turnaround time requirements. Whether your isolates are routine or require immediate attention, we have the operational flexibility and capacity to meet your needs. We also offer volume pricing

ABcann Global

Our group of companies will be the first to produce repeatable, standardized, plant-based medicines worldwide. ABcann will produce products with integrity in a customer focused culture where social responsibility and environmental impacts are mandated.

Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: TREXIMET®, SILENOR®, a non-narcotic product indicated for the treatment of insomnia characterized by difficulties with sleep maintenance, KHEDEZLA™, as well as CEDAX®, an antibiotic for middle ear infections. The Company promotes its branded products to physicians through its Pernix sales force and distributes its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is based in Morristown, New Jersey.

Eledon

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.